Dissertation
Dissertation > Medicine, health > Oncology > Genitourinary tumors > Breast tumor

Effect of HER-2 Gene on Anthracycline Adjuvant Chemotherapy Efficacy in Breast Cancer

Author DaiXie
Tutor ZhangXianZuo
School Guilin Medical College,
Course Surgery
Keywords Breast Cancer Adjuvant chemotherapy Human epidermal growth factor receptor 2 Estrogen Receptor Anthracycline
CLC R737.9
Type Master's thesis
Year 2010
Downloads 21
Quotes 0
Download Dissertation

Objective To investigate the HER-2 gene expression state application of the relationship between the anthracycline neoadjuvant chemotherapy in breast cancer patients, and to provide a theoretical basis for individualized treatment of patients. The method of systematic review of 204 patients with clinical stage Ⅱ of invasive breast cancer in patients with anthracycline state of survival after adjuvant chemotherapy and follow-up of 36 months. MaxVisionTM shortcut immunohistochemical assay tumor specimens HER-2 and ER expression. HER-2-based combination estrogen receptor, axillary lymph node metastasis group 204 patients, no difference between disease-free survival (DFS) the comparison groups different pathological features of patients in the application anthracycline chemotherapy. The results follow-up of 36 months, the total recurrence transfer rate of 35.29% (72/204), the mortality rate of 22.55% (46/204). (1) Overall, HER-2-positive patients DFS than HER-2-negative patients DFS high P lt; 0.05. (2) HER-2-positive patients with ER-positive DFS DFS than HER-2-negative patients with ER-positive high P lt; 0.05. (3) HER-2-positive patients with ER-negative than HER-2-negative patients with ER-negative DFS high P gt; 0.05. (4) patients with HER-2 expression in the same state, regardless of ER-negative or ER-positive the DFS are no significant differences between them, P GT; 0.05. (5) ER-negative and lymph node-negative patients, Her-2 negative group DFS below the Her-2 positive group, P lt; 0.05. () ER-negative and lymph node-positive patients with Her-2 negative group DFS than Her-2 positive group, P gt; 0.05. (7) ER-positive and lymph node-negative patients, Her-2 negative group DFS below the Her-2 positive group, P gt; 0.05. (8) ER-positive and lymph node-positive patients, the Her-2 negative group DFS below the Her-2 positive group, P lt; 0.05. (9) in the Her-2 negative group, ER-negative and node-negative patients with disease-free survival rate of less than the ER-negative and node-positive patients, P gt; 0.05; ER-positive and node-negative patients with the disease-free survival rate is higher than the ER positive and lymph node-positive patients, P gt; 0.05. (10) in the Her-2-positive group, ER-negative and node-negative patients with disease-free survival than disease-free survival rate than ER-positive and node-negative patients with ER-negative and lymph node-positive patients, P gt; 0.05; ER-positive and lymph node-positive patients, P gt; 0.05. (11) in the Her-2 negative group, ER-negative and node-negative patients with disease-free survival rate of less than the ER-positive and lymph node-negative patients, P gt; 0.05; ER-negative and lymph node-positive patients disease-free survival rate is lower than the ER positive and lymph node-positive patients, P gt; 0.05. (12) in the Her-2-positive group, ER-negative and node-negative patients with disease-free survival than ER-positive and node-negative patients, P gt; 0.05; ER-negative and node-positive patients with disease-free survival rate of less than ER-positive and lymph node-positive patients, P gt; 0.05. Conclusions (1) clinical stage Ⅱ patients with invasive breast cancer, HER-2 positive patients better than HER-2-negative patients from anthracycline adjuvant chemotherapy benefit. (2) HER-2 expression state as predicted Ⅱ clinical indicators of breast cancer patients with anthracycline adjuvant chemotherapy, especially in lymph nodes were negative for ER, ER, and lymph nodes were positive for these two types of patient populations. (3) combined with estrogen receptor status and lymph node metastasis, further screening Ⅱ clinical anthracyclines insensitive and negative ER-2 is relatively sensitive to anthracyclines in HER-2 positive breast cancer patients group

Related Dissertations
More Dissertations